Oncolytics Biotech (ONCY) EBITDA (2009 - 2026)
Oncolytics Biotech's (ONCY) quarterly EBITDA came in at -$9.4 million in Q2 2026, down 113.74% year-over-year from $68.3 million in Q2 2025, and up 11.53% quarter-over-quarter from -$10.6 million in Q3 2025.
Powered by 
Analysis
Oncolytics Biotech (ONCY) EBITDA (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported EBITDA for 18 consecutive years, with -$9.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA fell 113.74% year-over-year to -$9.4 million in Q2 2026; TTM through Jun 2026 was -$30.1 million, a 35.17% decrease from a year earlier, with the FY2025 full-year figure at -$28.7 million, down 12.42% from the prior year.
- EBITDA was -$9.4 million for Q2 2026 at Oncolytics Biotech, up from -$10.6 million in the prior quarter.
- Over five years, EBITDA peaked at -$2.9 million in Q4 2023 and troughed at -$10.6 million in Q3 2025.
- A 5-year average of -$6.1 million and a median of -$5.6 million in 2024 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 54.17% in 2023, down 118.99% in 2023.
- Over 5 years, EBITDA stood at -$6.3 million in 2022, then surged by 54.17% to -$2.9 million in 2023, then slumped by 99.45% to -$5.7 million in 2024, then slumped by 85.25% to -$10.6 million in 2025, then climbed by 11.53% to -$9.4 million in 2026.
- The last three EBITDA figures came in at -$9.4 million (Q2 2026), -$10.6 million (Q3 2025), and -$4.4 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.78 Bn | 192.79 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.74 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 60.35 Bn | 55.17 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.92 Bn | 30.63 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Oncolytics Biotech | 93.27 Mn | 93.27 Mn | - | -9.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.38 Mn |
| Sep 30, 2025 | -10.60 Mn |
| Jun 30, 2025 | -4.39 Mn |
| Dec 31, 2024 | -5.72 Mn |
| Sep 30, 2024 | -6.91 Mn |
| Jun 30, 2024 | -5.24 Mn |
| Dec 31, 2023 | -2.87 Mn |
| Sep 30, 2023 | -7.40 Mn |
| Jun 30, 2023 | -5.50 Mn |
| Dec 31, 2022 | -6.26 Mn |
| Sep 30, 2022 | -3.38 Mn |
| Jun 30, 2022 | -5.32 Mn |
| Dec 31, 2021 | -6.12 Mn |
| Sep 30, 2021 | -3.86 Mn |
| Jun 30, 2021 | -5.89 Mn |
| Dec 31, 2020 | -7.16 Mn |
| Sep 30, 2020 | -5.06 Mn |
| Jun 30, 2020 | -4.92 Mn |
| Sep 30, 2019 | -3.53 Mn |
| Jun 30, 2019 | -5.25 Mn |